Drugs / RGB-286638
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01168882 | Nov 2011 → Jun 2014 | hematopoietic and lymphoid cell neoplasm | Agennix | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGB-286638 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01168882 ↗ |
| Action | Inhibit | “novel, multi-targeted kinase inhibitor” NCT01168882 ↗6“Cyclin-dependent kinase 5 inhibitor” CHEMBL3545083 ↗ “Cyclin-dependent kinase 4 inhibitor” CHEMBL3545083 ↗ “Cyclin-dependent kinase 9 inhibitor” CHEMBL3545083 ↗ “Cyclin-dependent kinase 2 inhibitor” CHEMBL3545083 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL3545083 ↗ “Cyclin-dependent kinase 7 inhibitor” CHEMBL3545083 ↗ |
| Modality | Small molecule | — CHEMBL3545083 ↗ |
| Route | Intravenous | “given i.v.” NCT01168882 ↗ |
| Target | CDK1 | “Cyclin-dependent kinase 1 inhibitor” CHEMBL3545083 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL3545083 ↗ |
| Target | CDK4 | “Cyclin-dependent kinase 4 inhibitor” CHEMBL3545083 ↗ |
| Target | CDK5 | “Cyclin-dependent kinase 5 inhibitor” CHEMBL3545083 ↗ |
| Target | CDK7 | “Cyclin-dependent kinase 7 inhibitor” CHEMBL3545083 ↗ |
| Target | CDK9 | “Cyclin-dependent kinase 9 inhibitor” CHEMBL3545083 ↗ |